NO20061531L - Guanidinderivater - Google Patents

Guanidinderivater

Info

Publication number
NO20061531L
NO20061531L NO20061531A NO20061531A NO20061531L NO 20061531 L NO20061531 L NO 20061531L NO 20061531 A NO20061531 A NO 20061531A NO 20061531 A NO20061531 A NO 20061531A NO 20061531 L NO20061531 L NO 20061531L
Authority
NO
Norway
Prior art keywords
treatment
addictions
hyperalgesia
neuropeptide
pains
Prior art date
Application number
NO20061531A
Other languages
English (en)
Inventor
Kurt Hilpert
Volker Breu
Thomas Giller
Oliver Valdenaire
Heinz Fretz
Anja Fecher
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of NO20061531L publication Critical patent/NO20061531L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Oppfinnelsen angår guanidinderivater med den generelle formel (I)og hydrater eller solvater derav for anvendelse som nevropeptid FF reseptor-antagonister for behandling av smerte og hyperalgesi, av tilbaketrekningssymptomer ved avhengighet av alkohol, psykofarmaka og nikotin og under forebygging og behandling av slik avhengighet, for regulering av insulinsekresjon, matinntak, hukommelsesfunksjoner, blodtrykk og til elektrolytt og energimetabolisme og for behandling av urininkontinens.
NO20061531A 2003-09-05 2006-04-04 Guanidinderivater NO20061531L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH15262003 2003-09-05
PCT/CH2004/000556 WO2005023781A1 (de) 2003-09-05 2004-09-03 Guanidinderivate

Publications (1)

Publication Number Publication Date
NO20061531L true NO20061531L (no) 2006-04-04

Family

ID=34230846

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20061531A NO20061531L (no) 2003-09-05 2006-04-04 Guanidinderivater

Country Status (16)

Country Link
US (1) US7544691B2 (no)
EP (1) EP1663993B1 (no)
JP (1) JP2007504176A (no)
KR (1) KR20060064065A (no)
CN (1) CN1845907B (no)
AT (1) ATE388943T1 (no)
AU (1) AU2004270304A1 (no)
BR (1) BRPI0414103A (no)
CA (1) CA2536927A1 (no)
DE (1) DE502004006515D1 (no)
ES (1) ES2300807T3 (no)
IL (1) IL173853A0 (no)
NO (1) NO20061531L (no)
PL (1) PL1663993T3 (no)
RU (1) RU2006110738A (no)
WO (1) WO2005023781A1 (no)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE521512C2 (sv) 2001-06-25 2003-11-11 Niconovum Ab Anordning för administrering av en substans till främre delen av en individs munhåla
DK1803443T3 (en) 2002-12-20 2019-02-25 Niconovum Ab Nicotine-containing particulate material with a crystalline cellulose
CA2646942C (en) 2006-03-16 2014-07-29 Modoral Brands Inc. Improved snuff composition
CN102665406B (zh) * 2009-12-24 2016-03-09 诺沃梅尔公司 合成多环胍化合物的方法
WO2015002150A1 (ja) 2013-07-03 2015-01-08 株式会社新日本科学 新規化合物，有機カチオントランスポーター３の検出剤及び活性阻害剤
JP7153653B2 (ja) 2017-02-14 2022-10-14 リサーチ トライアングル インスティテュート プロリン系神経ペプチドｆｆ受容体モジュレーター
CN108159032A (zh) * 2018-01-24 2018-06-15 昆明理工大学 二甲双胍在制备预防和/或治疗阿片类毒品成瘾药物中的应用和药物及制备方法
CN108159031A (zh) * 2018-01-24 2018-06-15 昆明理工大学 二甲双胍在制备预防和/或治疗苯丙胺类毒品成瘾药物中的应用和药物及制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3505327A (en) 1967-08-07 1970-04-07 American Cyanamid Co Tetrahydroquinoxalinyl phosphates or thiophosphates
BE795257A (fr) 1972-02-10 1973-08-09 Thomae Gmbh Dr K Nouveaux oxazols
DE3334455A1 (de) * 1983-03-04 1984-09-06 Bayer Ag, 5090 Leverkusen Guanidin - derivate
US20030139431A1 (en) * 2001-09-24 2003-07-24 Kawakami Joel K. Guanidines which are agonist/antagonist ligands for neuropeptide FF (NPFF) receptors
WO2003026667A1 (en) * 2001-09-24 2003-04-03 Synaptic Pharmaceutical Corporation Quinazolino- and quinolino- guanidines as ligands for the neurop eptide ff (npff) receptors
WO2003026657A1 (en) * 2001-09-24 2003-04-03 Synaptic Pharmaceutical Corporation Compounds for the treatment of pain

Also Published As

Publication number Publication date
CN1845907A (zh) 2006-10-11
JP2007504176A (ja) 2007-03-01
ATE388943T1 (de) 2008-03-15
EP1663993B1 (de) 2008-03-12
CN1845907B (zh) 2010-07-28
DE502004006515D1 (en) 2008-04-24
CA2536927A1 (en) 2005-03-17
WO2005023781A1 (de) 2005-03-17
KR20060064065A (ko) 2006-06-12
IL173853A0 (en) 2006-07-05
PL1663993T3 (pl) 2008-08-29
BRPI0414103A (pt) 2006-10-31
RU2006110738A (ru) 2007-12-10
US20070123510A1 (en) 2007-05-31
US7544691B2 (en) 2009-06-09
ES2300807T3 (es) 2008-06-16
AU2004270304A1 (en) 2005-03-17
EP1663993A1 (de) 2006-06-07

Similar Documents

Publication Publication Date Title
MXPA05009855A (es) Derivados de guanidina y sus usos como antagonistas del receptor de neuropeptido ff.
CA2634676A1 (en) Trisubstituted amine compounds as inhibitors of cholesteryl ester transfer protein cetp
MX2007003321A (es) Derivados heterociclicos y su uso como agentes terapeuticos.
ECSP088974A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
NL300889I2 (nl) Trifluridine in combinatie met tipiracilhydrochloride
TW200626139A (en) Heterocyclic derivatives and their use as therapeutic agents
WO2006034440A3 (en) Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
BRPI0714908B8 (pt) derivados de pirimidina como inibidor de pi3k, composição farmacêutica e agente preventivo ou agente terapêutico de uma doença proliferativa que os compreende
WO2008002244A3 (en) Imidazol-pyrimidine derivatives for treatment of diseases related to glycogen synthase kinase (gsk3)
EA201000007A1 (ru) Производные индазоламида
WO2008108958A3 (en) Benzimidazole derivatives and methods of use thereof
NO20053742L (no) Tri (cyclo)-substituerte amidforbindelser
HRP20130406T1 (hr) Medikamenti s aktivnošä†u prema receptoru hm74a
JP2008515905A5 (no)
MX2007000028A (es) Derivados de nicotinamida y su uso como agentes terapeuticos.
TW200626153A (en) Heterocyclic derivatives and their use as therapeutic agents
NO20082445L (no) Neuropeptid-2 reseptor-agonister
EA201070164A1 (ru) Твердый препарат, включающий алоглиптин и гидрохлорид метформина
TW200626155A (en) Heterocyclic derivatives and their use as therapeutic agents
MX2007008614A (es) Peptidos con actividad agonista del receptor del neuropeptido-2 (y2r).
ATE388943T1 (de) Guanidinderivate
UA99485C2 (ru) Хиназолиндионовые производные, их получение и их применение в терапии
MA32639B1 (fr) [4-(5-aminométhyl-2-fluoro-phényl)-pipéridin- 1-yl]-[7-fluoro-1- (2-méthoxy-éthyl)-4-trifluorométhoxy-1h-indol-3-yl]-méthanone en tant qu'inhibiteur de la tryptase de mastocytes
WO2005042516A3 (en) Ligands of melanocortin receptors and compositions and methods related thereto
WO2003031407A3 (en) β-LACTAMYL VASOPRESSIN VlaANTAGONISTS

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application